Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Factor VII Antibodies:
anti-Human Factor VII Antibodies:
anti-Rat (Rattus) Factor VII Antibodies:
Go to our pre-filtered search.
Human Monoclonal Factor VII Primary Antibody for ELISA, RIA - ABIN4264232
Mahlangu, Paz, Hardtke, Aswad, Schroeder: TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. in Haemophilia : the official journal of the World Federation of Hemophilia 2016
Human Monoclonal Factor VII Primary Antibody for EIA, WB - ABIN951602
Kazama, Pastuszyn, Wildgoose, Hamamoto, Kisiel: Isolation and characterization of proteolytic fragments of human factor VIIa which inhibit the tissue factor-enhanced amidolytic activity of factor VIIa. in The Journal of biological chemistry 1993
Show all 4 Pubmed References
Human Polyclonal Factor VII Primary Antibody for IF (p), IHC (p) - ABIN1385638
Liu, Xue, Tang, Hou, Qi, Chen, Chen, Zhang, Chen, Xu: A simple method for isolating and culturing the rat brain microvascular endothelial cells. in Microvascular research 2013
Human Polyclonal Factor VII Primary Antibody for IHC (p), IHC - ABIN441425
Naderi: Coagulation factor VII is regulated by androgen receptor in breast cancer. in Experimental cell research 2015
Hepsin (show HPN Antibodies) plays a physiologically important role in factor VII (show TH Antibodies) activation and hemostasis in zebrafish.
study reports the full-length cDNA sequences of rhesus monkey FVII; deduced protein sequence of FVII indicates the functional domains; comparison of three-dimensional protein structure with human shows high conservation between them
FVIIa binding to EPCR (show PROCR Antibodies) leads to a barrier protective effect in vivo
FVIIa binding to EPCR (show PROCR Antibodies) on the endothelium facilitates the transport of FVIIa from circulation to extravascular tissues where TF resides
Murine FVIIa binds poorly to murine EPCR (show PROCR Antibodies).
Conclude that the fVII-targeted verteporfin photodynamic therapy that we report here is a novel and effective therapeutic with improved selectivity for the treatment of breast cancer.
The participation of Egr-1 (show EGR1 Antibodies) in FVIIa-mediated regulation of keratinocyte function was confirmed by use of Egr-1 (show EGR1 Antibodies)-deficient mice, wherein a significant delay in skin wound healing after injury was observed, relative to WT mice.
Recombinant FVIIa readily associates with the vascular endothelium and subsequently enters into extravascular spaces where it is likely to bind to tissue factor (show F3 Antibodies) and is retained for extended time periods.
Gene targeting of tissue factor (show F3 Antibodies), factor X, and factor VII (show TH Antibodies) in mice: their involvement in embryonic development
true circadian rhythms for FVII were found
Data suggest that long-term expression of murine activated factor VII (show TH Antibodies) is safe, but elevated levels cause premature mortality.
tissue factor (show F3 Antibodies)/Factor VIIa/PAR2 (show F2RL1 Antibodies) signaling mediates neutrophil activation and fetal death in antiphospholipid syndrome and that statins may be a good treatment for women with aPL (show FASL Antibodies)-induced pregnancy complications.
Data suggest that, for all coagulation proteins tested (prothrombin, factor X, activated factor VII, activated protein C), tighter binding to lipid bilayers (lower Kd) is observed as the proportion of anionic phospholipid increases. These studies were conducted in high-throughput screening using phospholipid bilayers in nanodiscs with multiplexed silicon photonic sensor (micro-ring resonator) array technology.
A coagulation initiating pathway is revealed in which the TF-FVIIa-nascent FXa (show F10 Antibodies) complex activates FVIII (show F8 Antibodies) apart from thrombin (show F2 Antibodies) feedback.
Data suggest activation of PAR2 (show F2RL1 Antibodies) via FVIIA/TF signaling activates PI3K (show PIK3CA Antibodies)/AKT (show AKT1 Antibodies) signaling, inactivates GSK3b (show GSK3b Antibodies) signaling, leads to accumulation of beta-catenin (show CTNNB1 Antibodies), and promotes tumor cell migration/invasion. (PAR2 (show F2RL1 Antibodies) = protease-activated receptor 2 (show F2RL1 Antibodies); FVIIA = coagulation factor VIIa; TF = tissue factor/thromboplastin (show F3 Antibodies); PI3K (show PIK3CA Antibodies) = phosphatidylinositol 3-kinase; AKT (show AKT1 Antibodies) = proto-oncogene (show RAB1A Antibodies) protein c (show PROC Antibodies)-akt (show AKT1 Antibodies); GSK3b (show GSK3b Antibodies) = glycogen synthase kinase 3 beta (show GSK3b Antibodies))
heterozygotes for FVII deficiency show rare bleeding manifestations which are also present in the unaffected family members with normal FVII levels. This indicates that Factor VII (show TH Antibodies) activity levels played no role in the occurrence of the bleeding symptoms. Furthermore, FVII levels of around 0.40 IU/dl are capable of assuring a normal hemostasis.
Family-based association study revealed that the G allele of Protein Z (show PROZ Antibodies) rs2273971, and haplotypes GA, CG, and CGA (show CGA Antibodies) of Protein Z (show PROZ Antibodies) and factor VII (show TH Antibodies) had a significant effect on cerebral hemorrhage susceptibility.
Circulating FVII, FVIIa and TFPI (show TFPI Antibodies) were significantly elevated in women with severe preeclampsia in the absence of comparable changes in plasma TF levels.
Our study findings suggest a link between FVII and AR in prostate cancer pathogenesis.
Large deletions play a minor but essential role in the mutational spectrum of the F7 and F10 (show F10 Antibodies) genes. Copy number analyses (e. g. MLPA) should be considered if sequencing cannot clarify the underlying reason of an observed coagulopathy. Of note, in cases of combined FVII/FX deficiency, a deletion of the two contiguous genes might be part of a larger chromosomal rearrangement.
Structure-Function Relationship of the Interaction between Tissue Factor (show F3 Antibodies) and Factor VIIa.
Data suggest that allosteric regulation of FVIIa activity by tissue factor/thromboplastin (show F3 Antibodies) binding appear to involve direct interaction with FVIIa active site, stabilizing segment 215-217, activating loop 3, and leading to enhanced FVIIa activity.
This gene encodes coagulation factor VII which is a vitamin K-dependent factor essential for hemostasis. This factor circulates in the blood in a zymogen form, and is converted to an active form by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of the factor VII, a heavy chain containing a catalytic domain and a light chain containing 2 EGF-like domains are generated, and two chains are held together by a disulfide bond. In the presence of factor III and calcium ions, the activated factor then further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Defects in this gene can cause coagulopathy. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
coagulation factor VII
, clotting factor
, serum prothrombin conversion accelerator
, FVII coagulation protein
, eptacog alfa